<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    How did Prime Medicine's expenses impact its revenue in Q4 2024?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        5/9/2025 02:34pm
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">Prime Medicine's expenses had a significant negative impact on its revenue in Q4 2024. Despite generating $2.18 million in revenue, the company incurred total expenses of $42.28 million, resulting in a substantial net loss. This indicates that the company's expenses far exceeded its revenue during the period, likely due to factors such as high operational costs, research and development expenditures, or strategic investments. The resulting negative net income reflects the challenges Prime Medicine faced in managing its costs relative to its revenue generation during that quarter.


|code|Ticker|Name|Date|Total Revenue|Total Expenses|Net Income|market_code|
|---|---|---|---|---|---|---|---|
|PRME|PRME.O|Prime Medicine|2023 Q4|||-6.5643E7|185|
|PRME|PRME.O|Prime Medicine|2024 Q1|591000||-4.5761E7|185|
|PRME|PRME.O|Prime Medicine|2024 Q2|||-5.5327E7|185|
|PRME|PRME.O|Prime Medicine|2024 Q3|209000||-5.2518E7|185|

</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak,al,am,an,ao,ap,aq,ar,as,at){return {layout:"default",data:[{noData:c,currentQuestion:g,textDescription:V,comeFrom:"AInvestShareLink",events:[],answerSource:n}],fetch:{},error:o,state:{sharePreviewModule:{loadJgySuccess:d,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:h,agent_id:a,output_media_info:[],task_id:a,language:a,source:n,cache_builder:a,reply_action:"Answer",execute_mode:G,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"How did Prime Medicine's expenses impact its revenue in Q4 2024?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"How did Prime Medicine's expenses impact its revenue in Q4 2024?\",\"user_id\":\"dp09422551\",\"user_name\":\"\",\"trace_id\":\"f2334054-1179-4040-8117-fb861d46a696\",\"session_id\":\"f2334054-1179-4040-8117-fb861d46a696\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"query_data",query_type:j,text:"1 results found:\n|stock code|stock name|Last Price|Last Change|Total Revenue[20241231]|Total Expenses[20241231]|Net Income[20241231]|Report End Date|\n|---|---|---|---|---|---|---|---|\n|PRME|Prime Medicine|$1.32|-7.04%|$2.18 million||-$42.28 million|20241231|\n",query_data:{number:h,title:H,query_type:j,condition:a,model_sql:W,data_ext_params:{merge_repeat:c,expand_index:b,data_add:h,add_index:d}}}],answer_chain_name:X,agent_mode:Y,native_answer:a,come_from:a,text_answer:V,trace_id:i,cost:15407,event_names:a,question:g,fallback_type:Z,input_type:_,fall_back_reason:{fall_back_type:Z,may_fall_back_reason:"UNKNOWN",risk_detail:{matched_words:[]}},session_id:i,first_return_cost:2538,cache_type:"no_cache",question_id:i,transfer_question:g,signal_type:"ON_COMPLETE",start_time:I,remote_svc:n,slots:[],answer_type:G,user_id:x,skill_name:J},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:i,session_id:i,user_id:x,question:g,source:n,raw_question:g,version:"3.4.1",action_name:J,nlu:{entity:[{type:$,value:p,market:k}]},output_time:I,deep_research:c,deep_thinking:c,agent_mode:Y},extra:{}},{answer_path:y,section:{id:z,info_texts:["Thinking"],show_type:A,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:y,section:{id:z,info_texts:["Querying Stock: PRME Revenue, Total Expenses, Net Income in Q4 2024"],show_type:A,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"thinking"},logs:[],extra:{action:"Querying Stock",action_input:H,thought:"The user wants to analyze how Prime Medicine's expenses impacted its revenue in Q4 2024. I should focus on its revenue, total expenses, and net profit data for Q4 2024. I will use FinQuery for the data mentioned above."}},{answer_path:e,section:{id:q,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:q,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:y,section:{id:z,info_texts:["Generating Answer"],show_type:A,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:e,section:{id:r,info_texts:[],show_type:B,voice_txt:"Prime",text_answer:aa,rich_text:aa,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:2000,info_texts:[],show_type:B,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{title:H,query_type:j,trace_data:a,index:h,model_sql:W,data_ext_params:{merge_repeat:c,expand_index:b,data_add:h,add_index:d},jump_type:"data_query"}],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:q,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:q,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:q,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:r,info_texts:[],show_type:B,voice_txt:".\n\n",text_answer:ab,rich_text:ab,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:s,market_id:k,name:m,domain:$},pos:d,section_id:r,txt:m,jump_type:"pos_fenshi"}],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:r,info_texts:[],show_type:ac,choice:[],result_page:{components:[{uuid:"bcfd048ad0de9a17",config:{score:116,show_type:ad,scoreRuleNames:"value_unit;data_size;",showDataZoom:b,show_type_id:131,title:"分组柱状图",render:{x:t,y:[C,D]},title_config:{config:{display:b,display2:c,txt_style:d,url:a},data:{h1:ae,h2:a},show_type:K}},data:{chunks_info:"[]",code_count:h,columns:[{index_name:L,key:L,label:"hq_code",source:M,type:f},{domain:u,feKey:N,index_name:N,key:N,label:L,origin_index:"stock code",source:M,type:f,unit:a},{domain:u,feKey:O,index_name:O,key:O,label:"name",origin_index:"stock name",source:M,type:f,unit:a},{feKey:t,index_name:t,key:t,label:"date",origin_index:t,type:"DATE"},{domain:u,feKey:C,index_name:C,key:C,label:a,source:a,timestamp:a,type:P,unit:Q},{domain:u,feKey:R,index_name:R,key:R,label:a,source:a,timestamp:a,type:P,unit:Q},{domain:u,feKey:D,index_name:D,key:D,label:a,source:a,timestamp:a,type:P,unit:Q},{index_name:af,key:af,type:f}],condition:"[{\"sonSize\":5,\"opName\":\"and\",\"relatedSize\":0},{\"sonSize\":0,\"indexName\":\"国际美股@stock code\",\"indexProperties\":[\"EQUAL PRME.O\"],\"indexPropertiesMap\":{\"EQUAL\":\"PRME.O\"},\"domain\":\"abs_国际美股领域\",\"relatedSize\":0},{\"sonSize\":3,\"opName\":\"or\",\"relatedSize\":0},{\"sonSize\":0,\"indexName\":\"国际美股@Total Expenses\",\"indexProperties\":[\"起始交易日期 20231001\",\"截止交易日期 20240930\"],\"indexPropertiesMap\":{\"起始交易日期\":\"20231001\",\"截止交易日期\":\"20240930\"},\"domain\":\"abs_国际美股领域\",\"relatedSize\":0},{\"sonSize\":0,\"indexName\":\"国际美股@Net Income\",\"indexProperties\":[\"起始交易日期 20231001\",\"截止交易日期 20240930\"],\"indexPropertiesMap\":{\"起始交易日期\":\"20231001\",\"截止交易日期\":\"20240930\"},\"domain\":\"abs_国际美股领域\",\"relatedSize\":0},{\"sonSize\":0,\"indexName\":\"国际美股@Total Revenue\",\"indexProperties\":[\"起始交易日期 20231001\",\"截止交易日期 20240930\"],\"indexPropertiesMap\":{\"起始交易日期\":\"20231001\",\"截止交易日期\":\"20240930\"},\"domain\":\"abs_国际美股领域\",\"relatedSize\":0}]",dataSize:4,datas:[{"Net Income":-65643000,code:s,Ticker:p,market_code:k,Date:"2023 Q4",Name:m},{"Net Income":-45761000,code:s,"Total Revenue":591000,Ticker:p,market_code:k,Date:"2024 Q1",Name:m},{"Net Income":-55327000,code:s,Ticker:p,market_code:k,Date:"2024 Q2",Name:m},{"Net Income":-52518000,code:s,"Total Revenue":209000,Ticker:p,market_code:k,Date:"2024 Q3",Name:m}],meta:{extra:{}},row_count:h,status_code:d,status_msg:"ok"},category:"generic",chart_type:"groupedBar",show_type:ad,title_config:{config:{display:b,display2:c,txt_style:d,url:a},data:{h1:ae,h2:a},show_type:K},support_refresh:b,data_config:{query:a,query_type:j,data_ext_params:{}}}],global:{query_type:j},page:{language:a,layout:{layout_data:"[{\"children\":[],\"showType\":\"bar3\",\"uuid\":\"bcfd048ad0de9a17\"}]"},render_for:S},data_config:{query:a,query_type:j,data_ext_params:{}}},tag_info_list:[],is_last:c,uuid:"34d95f84-ae21-4f74-b367-f2d173a5a8ec"},logs:[],extra:{}},{answer_path:e,section:{id:r,info_texts:[],show_type:B,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:y,section:{id:z,info_texts:["Completed"],show_type:A,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:ac,choice:[{display_text:v,query_text:v,trace_info:{item_id:"9234af3155fc44383cfda967b24da557",item_type:E,item_name:v,rec_info:ag}},{display_text:w,query_text:w,trace_info:{item_id:"8dd73584925fac767bd12fa1315eed73",item_type:E,item_name:w,rec_info:ah}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:K,data:{h1:a,h2:a},config:{display:c,txt_style:d,type:"1",display2:c,url:a}},request_config:[{source_type:3,related_name:ai}],puuid:T,tag:a,category:"custom",uuid:aj}],global:{urp_static_data:[{name:ai,value:{status_code:d,columns:[{type:f,index_name:ak,key:ak},{type:f,index_name:al,key:al},{type:f,index_name:am,key:am},{type:f,index_name:an,key:an},{type:f,index_name:ao,key:ao}],datas:[{send_text:v,item_type:E,rec_info:ag,display_text:v,rec_reason:a},{send_text:w,item_type:E,rec_info:ah,display_text:w,rec_reason:a}],dataSize:2,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:9999,label:ap,type:"thslc\u002Fthslc-common-container",leaf:c,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:b,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:F,"min-height":"100%",position:aq,height:F},isMaterial:c,id:ap,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:d,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:U,componentUuid:aj,script:[{name:ar,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:U,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:U},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:F,position:aq,height:F},isMaterial:b,_id:19,id:ar,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:S,voice_txt:a,tracking_info:{},uuid:T},order:{is_auto:c,render_for:S,chart_type:"command",puuid:T}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1003,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:J,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:G,answer_chain_name:X},is_deep_research:c,deep_thinking:c,create_time:1746772486047},is_last:b}],questionItem:{data:{qStr:g,encodeFlag:c,imageData:o,docsData:[],quoteData:o},tplType:"question"},events:as,agentId:a,param:{entity_info:{},add_info:{ori_question:g},event_list:as,client_ip:a,question:g,user_id:x,user_name:a,trace_id:i,session_id:i,source:n,input_type:_}}],userId:x,userName:a,startTime:I,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:o,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],chatTraceTargetIndex:d,traceTableData:o,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fhow-did-prime-medicines-expenses-impact-its-revenue-in-q4-2024-ead917\u002F",config:{_app:{basePath:at,assetsPath:at,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,0,"other\u002FopenAnswer","STR","How did Prime Medicine's expenses impact its revenue in Q4 2024?",1,"f2334054-1179-4040-8117-fb861d46a696","intusstock","185","signal","Prime Medicine","ths_ainvest_lite_web",null,"PRME.O",999,2001,"PRME","Date","abs_国际美股领域","💲 What were the major expense categories for Prime Medicine in Q4 2024?","📊 How did Prime Medicine's Q4 2024 expenses affect its overall profitability?","dp09422551","progress\u002Fsearching_for",1000,"searching_for","rich_text","Total Revenue","Net Income","llm_generated","auto","agent","PRME Revenue, Total Expenses, Net Income in Q4 2024",1746772470640,"explain news events","title1","code","fixed_index","Ticker","Name","DOUBLE","USD","Total Expenses","aigc","39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","Prime Medicine's expenses had a significant negative impact on its revenue in Q4 2024. Despite generating $2.18 million in revenue, the company incurred total expenses of $42.28 million, resulting in a substantial net loss. This indicates that the company's expenses far exceeded its revenue during the period, likely due to factors such as high operational costs, research and development expenditures, or strategic investments. The resulting negative net income reflects the challenges Prime Medicine faced in managing its costs relative to its revenue generation during that quarter.\n\n\n|code|Ticker|Name|Date|Total Revenue|Total Expenses|Net Income|market_code|\n|---|---|---|---|---|---|---|---|\n|PRME|PRME.O|Prime Medicine|2023 Q4|||-6.5643E7|185|\n|PRME|PRME.O|Prime Medicine|2024 Q1|591000||-4.5761E7|185|\n|PRME|PRME.O|Prime Medicine|2024 Q2|||-5.5327E7|185|\n|PRME|PRME.O|Prime Medicine|2024 Q3|209000||-5.2518E7|185|\n\n","select   stock_code,   total_revenue,   total_expenses,   net_income from   ustock_fin_data where   report_end_date = date('2024y4q')   and stock_code = 'PRME.O'","agent_common_v2\nagent-summary","normal_agent","NONE","typewrite","stock","Prime Medicine's expenses had a significant negative impact on its revenue in Q4 2024. Despite generating $2.18 million in revenue, the company incurred total expenses of $42.28 million, resulting in a substantial net loss. This indicates that the company's expenses far exceeded its revenue during the period, likely due to factors such as high operational costs, research and development expenditures, or strategic investments. The resulting negative net income reflects the challenges Prime Medicine faced in managing its costs relative to its revenue generation during that quarter[^1]",".\n\n\n``` visual\n{\"uuid\":\"34d95f84-ae21-4f74-b367-f2d173a5a8ec\"}\n```","result_page","bar3","PRME Total Revenue, Net Income","market_code","2+679_496_21_554+0+0+f2334054-1179-4040-8117-fb861d46a696+9234af3155fc44383cfda967b24da557+llm_generated+aimeTagAnalysis+0+0.017858052626252174+1","2+679_496_21_554+0+0+f2334054-1179-4040-8117-fb861d46a696+8dd73584925fac767bd12fa1315eed73+llm_generated+aimeTagAnalysis+0+0.0042269546538591385+2","recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>